Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1321-1329

  Yim, E K ^a   Lee, S B ^a   Lee, K H ^a   Kim, C J ^a   Park, J S ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

5 fluorouracil (5 FU); Apoptosis; Cervical cancer; Cisplatin (CP); Proteomics

Indexed keywords

ANTIMITOTIC AGENT; CISPLATIN; FLUOROURACIL; PROTEIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MITOCHONDRION; PRIORITY JOURNAL; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HELA CELLS; HUMANS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 33745177361     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00551.x     Document Type: Article

References (23)

1. Parikh S Brennan P Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003 10: 687 91.
2. Grigsby PW Perez CA Chao KS et al. Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix stage IB and IIA treated with preoperative irradiation and surgery. Int J Radiat Oncol Biol Phys 1999 1: 645 51.
3. Bonomi P Blessing JA Stehman FB DiSaia PJ Walton L Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985 3: 1079 85.
4. Cohen SM Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 2001 67: 93 130.
5. Fichtinger-Schepman AM Dijt FJ Bedford P et al. Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques. IARC Sci Publ 1988 89: 321 8.
6. Zamble DB Mu D Reardon JT Sancar A Lippard SJ. Repair of cisplatin - DNA adducts by the mammalian excision nuclease. Biochemistry 1996 6: 10004 13.
7. Morris M Eifel PJ Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999 15: 1137 43.
8. Thomas CR Giroux DJ Janaki LM et al. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer 2001 33: 213 9.
9. Esaki T Nakano S Tatsumoto T et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992 1: 6501 6.
10. Omura G Shingleton H Creasman W Blessing JA Boronow RC. Chemotherapy of advanced gynecologic cancer with nitrosoureas: a randomized trial of CCNU and methyl CCNU in carcinoma of the cervix, corpus, vaginal, vulva, and tube. Cancer Treat Res 1978 62: 833 5.
11. Thigpen T Vance R Lambuth B et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 1987 60: 2104 16.
12. Vermorken JB. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer 1993 3: 129 42.
13. Nezhat F Wadler S Muggia F et al. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 2004 93: 144 8.
14. Ries LAG Eisner MP Kosary CL et al. SEER cancer statistic review. Bethesda, MD: National Cancer Institute, 1975 2000.
15. Tattersall MHN Ramirez C Coppleson M. A randomised trial comparing platinum-based chemotherapy followed by radiotherapy vs. radiotherapy alone in patients with locally advanced cervical cancer. Int J Gynecol Cancer 1992 21: 244 51.
16. Petterson F. 21st annual report on the result of treatment in gynaecological cancer. Int J Gynaecol Obstet 1991 36 ( Suppl 27 130.
17. Yim EK Lee KH Bae JS Namkoong SE Um SJ Park JS. Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol 2004 23: 769 76.
18. Begg AC Bohlken S Bartelink H. The effect of cisplatin on the repair of radiation damage in RIF1 mouse tumours in vivo. Radiother Oncol 1989 15: 79 91.
19. Britten RA Evans AJ Allalunis-Turner MJ Pearcey RG. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys 1996 15: 367 74.
20. Jacobs C Lyman G Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992 10: 257 63.
21. Diaz-Rubio E Jimeno J Anton A et al. A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D Am J Clin Oncol 1992 15: 56 60.
22. Scanlon KJ Newman EM Lu Y Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 1986 83: 8923 25.
23. Rich TA Ajani JA Morrison WH Ota D Levin B. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 1993 27: 209 15.